Novo Nordisk Rises After Hims Withdraws $49 Compounded Weight-Loss Pill
Novo Nordisk shares jumped sharply in Copenhagen after telehealth company Hims Hers Health pulled a newly launched $49 compounded weight-loss pill that used semaglutide, following pressure from Novo and the U.S. Food and Drug Administration. The FDA said it will tighten oversight of compounded GLP-1 products, and Novo confirmed it will pursue legal…